NVC Test in Order to Assess Pathological Changes in Family Members of Patient Diagnosed With SSc
NCT02795221 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2016-06-10
Summary
Systemic sclerosis (SSc) is multisystem autoimmune disease of unknown etiology. It's characterized by activation of immune system, microvascular changes and intimal proliferation.
The EULAR/ACR 2013 criteria for the classification of SSc will help identify SSC patients before fibrosis of internal organs and will allow early treatment.
Patient with RP, SSc-related autoAb, anti-topoisomerase I (SCL-70), anti-centromere autoAb, anti-RNApolymerase III, abnormal nailfold capillaries and puffy hands would have SSc.
The OR of abnormal capillaroscopy for subsequent development of SSc can reach 163 with positive predictive value of 52% and negative predictive value of 99% .Some studies found that preclinical internal organ involvement in pre-scleroderma patients, DLCO\<80% was detected in 11/32 patients with RP plus SSc-associated autoAb plus SSc-type nailfold capillary changes.
The heritability of SSc was considered controversial in the, largest published SSc .Twin study, which in general suggested a modest genetic contribution to the Phenotype .Nevertheless, this study included only 42 sets of twins, and it should Be considered that, in a family study of 703 cases, an affected first-degree relative Increased the risk of SSc 13 times compared to the general population . Moreover, having an affected sibling increased SSc risk by 15 times , and there Was a remarkable concordance of auto antibodies between SSc twins . Additionally, recent analyses have shown that the standardized incidence ratio of SSc seemed to be less than those observed in autoimmune diseases (ADs) such as Rheumatoid arthritis or Ankylosing Spondylitis, but similar to those observed for Hashimoto, thyroiditis or psoriasis. In addition, SSc prevalence, clinical Outcomes and autoantibody profiles have been reported to vary depending on Patient ancestry Therefore, the role of genetic factors in SSc susceptibility can now be considered solidly established.
A positive family history of SSc appears to confer a risk that is at least 10-16-fold Higher than normal for SSc in first-degree relatives and 10-27-fold higher than Normal for SSc in siblings, and thus represents the strongest susceptibility factor Yet reported for this disease .
Conditions
- According to the IRB Approval
Sponsors & Collaborators
-
Meir Medical Center
lead OTHER
Eligibility
- Min Age
- 3 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-06-30
- Primary Completion
- 2017-06-30
- Completion
- 2017-06-30
More Related Trials
-
AUTOANTIBODIES AND SYSTEMIC SCLEROSIS
NCT06502678 ·Status: NOT_YET_RECRUITING
-
Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis
NCT00318188 ·Status: COMPLETED ·Phase: NA
-
Oral Manifestations of Systemic Sclerosis
NCT02371005 ·Status: TERMINATED ·Phase: NA
-
SCLERoderma et Adipose-DErived Stroma Cells
NCT02866552 ·Status: UNKNOWN ·Phase: PHASE2
-
Injection of Autologous Adipose-derived Stromal Vascular Fraction in the Finger of Systemic Sclerosis Patients
NCT03060551 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis
NCT05177380 ·Status: UNKNOWN ·Phase: NA
-
Metabolomic Analysis of Systemic Sclerosis
NCT02298777 ·Status: TERMINATED
-
Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis
NCT02558543 ·Status: TERMINATED ·Phase: PHASE2
-
EFFECTS OF THE MICRO REINJECTION OF AUTOLOGOUS ADIPOSE TISSUE IN THE FACE OF PATIENTS WITH SYSTEMIC SCLEROSIS
NCT02206672 ·Status: UNKNOWN ·Phase: NA
-
Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre
NCT04265144 ·Status: RECRUITING ·Phase: NA
-
Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis
NCT06462768 ·Status: RECRUITING
-
High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis
NCT00428883 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients
NCT03558854 ·Status: COMPLETED ·Phase: PHASE4
-
CSL Behring Sclero XIII
NCT02551042 ·Status: UNKNOWN ·Phase: PHASE2
-
Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis
NCT00667134 ·Status: COMPLETED
-
Calcinosis in a Single-Center Scleroderma Population
NCT02062125 ·Status: COMPLETED
-
Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis
NCT02636127 ·Status: COMPLETED ·Phase: NA
-
Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis.
NCT01743612 ·Status: COMPLETED ·Phase: NA
-
Scleroderma: Functional Disability Between the Dominant and Contralateral Hand.
NCT05171114 ·Status: COMPLETED ·Phase: NA
-
The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)
NCT02887495 ·Status: COMPLETED
-
Catestatin as a Novel Biomarker for Cardiovascular and Microvascular Involvement in Systemic Sclerosis
NCT07209644 ·Status: NOT_YET_RECRUITING
-
Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis
NCT02212249 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis
NCT03508375 ·Status: UNKNOWN ·Phase: NA
-
Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis
NCT00668473 ·Status: COMPLETED
-
Prevalence of Hyperprolactinemia in Systemic Scleroderma
NCT04746313 ·Status: COMPLETED